Haddadi et al., 2022 - Google Patents
Signs, symptoms and complications of non-Hodgkin's lymphoma according to grade and stage in south IranHaddadi et al., 2022
View PDF- Document ID
- 10515334303071743683
- Author
- Haddadi S
- Dehghani M
- Vojdani R
- Publication year
- Publication venue
- International Journal of Collaborative Research on Internal Medicine & Public Health
External Links
Snippet
Background: Non-Hodgkin's lymphoma (NHL) is a heterogeneous type of neoplasm of the lymphatic system. In order to have a more accurate and early diagnosis we need to be familiar with signs, symptoms and complications of lymphoma in early stages besides …
- 206010029592 Non-Hodgkin's lymphomas 0 title abstract description 24
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | The gut microbiome: what the oncologist ought to know | |
| Martín et al. | Faecalibacterium: a bacterial genus with promising human health applications | |
| Qu et al. | Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer | |
| Huang et al. | Effects of microbiota on anticancer drugs: Current knowledge and potential applications | |
| Longhi et al. | Microbiota and cancer: the emerging beneficial role of bifidobacteria in cancer immunotherapy | |
| JP7366744B2 (en) | Microbiota composition as a marker of reactivity to anti-PD1/PD-L1/PD-L2 antibodies and microbial modulators to improve the efficacy of anti-PD1/PD-L1/PD-L2 antibody-based therapeutic agents. Use of | |
| Xie et al. | Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies | |
| JP2023029829A (en) | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | |
| Davar et al. | Facts and hopes for gut microbiota interventions in cancer immunotherapy | |
| JP2021514968A (en) | Microbial immunotherapy | |
| Xie et al. | The role of the gut microbiota in tumor, immunity, and immunotherapy | |
| JP2025041753A (en) | Treatment of inflammatory bowel disease with 2'-fucosyllactose compounds | |
| Masetti et al. | The gut microbiome in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation | |
| Shi et al. | Emerging roles of the gut microbiota in cancer immunotherapy | |
| CN116709924A (en) | Designer bacterial compositions for the treatment of graft-versus-host disease | |
| Yan et al. | Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes | |
| Liu et al. | Influence of the gut microbiota on immune cell interactions and cancer treatment | |
| Pham et al. | Cancer and immunotherapy: a role for microbiota composition | |
| Wang et al. | The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer | |
| Wang et al. | Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors | |
| Jamal et al. | Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology | |
| Kumar et al. | The cure from within? a review of the microbiome and diet in melanoma | |
| Yu et al. | Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+ CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib | |
| Yang et al. | Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma | |
| Machida et al. | Immunotherapy and microbiota for targeting of liver tumor-initiating stem-like cells |